|Former: Atención Farmacéutica|
|Journal edited by Rasgo Editorial since 1983|
Manuela Velázquez Prieto
EDITOR IN CHIEF
Jaime E. Poquet Jornet
Tomás Casasín Edo
Virginia Hernández Corredoira
Ramón Jódar Masanés
Juan Carlos Juárez Giménez
Volume 19 - Issue 5, September-October 2017
REVIEW OF ABSENCE OR PRESENCE OF LACTOSE IN ORAL CYTOSTATIC DRUGS
PELEGRÍN TORRES PALOMA, ARIAS MOYA MARÍA ÁNGELES, MARTÍN GOZALO EVA MARÍA, FORTE PÉREZ-MINAYO MARÍA, HERNÁNDEZ SEGURADO MARTA, BÉCARES MARTÍNEZ FRANCISCO, CASTILLO BAZÁN EVA
Objective: To collect data about the presence or absence of lactose in oral cytostatics. The datasheets of 281 pharmaceutical specialties, of different doses and laboratories, corresponding to 55 different cytostatic drugs have been reviewed.
Method: We reviewed all brands and generic medicinal products (EFG), all available doses and different drug presentations for each active substance within the L group (antineoplastic). A bibliographic search has been made about the absence or presence and quantity of lactose as an excipient in the summary of product characteristics or in the package leaflet.
Results: We reviewed 281 pharmaceutical specialties, corresponding to 55 active substances with their corresponding doses. 31 active substances do not include lactose between their excipients. The amount of lactose varies according to the manufacturer laboratory and the dose of the drug within a range between
1.9 mg and 456 mg. Only in two active substances with EFG (imatinib and tamoxifen), we currently have lactose-free EFG as an alternative.
Conclusions: The pharmacist can play an important role in this field during the care of the onco-hematological patient, providing information and detecting problems related to the medication, as well as informing the prescribing physician in the case of prescribing a drug with lactose in a patient with intolerance to lactose.
INTOLERANCE – LACTOSE – ORAL CYTOSTATICS